The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents 7-year follow-up data from the ECHELON-2 trial (NCT01777152), focusing on the utilization of positron emission tomography (PET) imaging to assess outcomes of treatment with brentuximab vedotin plus CHP versus standard-of-care (SoC) CHOP in patients with CD30-positive mature T-cell lymphomas. The findings reveal that PET imaging after 4 cycles of treatment can prognosticate long-term outcomes, highlighting the importance of incorporating PET imaging into clinical practice to guide treatment plans. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Salarius, Acrotech, CRISPR, Seagen, Yingli; Research Funding: Pfizer, Ono, Astra Zeneca, Legend, Acrotech, Innate, CRISPR, Seagen, Merck, Drenbio, Yingli; Speakers Bureau: CuraBio, American Society of Hematology, American Society of Transplant and Cellular Therapy.
